Trial · NCT06935409
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
NCT06935409, Phase 3, Completed, Hansoh BioMedical R&D Company
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure. Trials, record NCT06935409. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06935409
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
- NCT number
- NCT06935409
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 122 participants, actual
- Lead sponsor
- Hansoh BioMedical R&D Company
- Conditions
- Osteosarcoma
- Interventions
- HS-20093, Gemcitabine combined with docetaxel
- First posted
- 2025-04-20
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PFS assessed by IRC as per RECIST 1.1 criteria | From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 5 years. | PFS is defined as the time interval from the randomization to disease progression as per ICR assessment or death due to any cause. |
| Secondary | ORR assessed by IRC as per RECIST 1.1 criteria | From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 5 years | Confirmed ORR is defined as the sum of the complete response (CR) rate and partial response (PR) rate as per ICR per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 |
| Secondary | DCR assessed by IRC as per RECIST 1.1 criteria | From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 5 years | Disease control rate is defined as the proportion of participants who have achieved a best overall response of confirmed CR, confirmed PR, or SD (or non-CR/non-PD) per ICR per RECIST v1.1 |
| Secondary | DoR assessed by IRC as per RECIST 1.1 criteria | From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 5 years | Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first documentation of progressive disease (PD) or death |
| Secondary | ORR assessed by the investigator as per RECIST 1.1 criteria | From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 5 years | Confirmed ORR is defined as the sum of the complete response (CR) rate and partial response (PR) rate as per investigator per RECIST v1.1 |
| Secondary | DCR assessed by the investigator as per RECIST 1.1 criteria | From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 5 years | Disease control rate is defined as the proportion of participants who have achieved a best overall response of confirmed CR, confirmed PR, or SD (or non-CR/non-PD) per investigator assessment per RECIST v1.1 |
| Secondary | DoR assessed by the investigator as per RECIST 1.1 criteria | From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 5 years | Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first documentation of progressive disease (PD) or death |
| Secondary | PFS assessed by the investigator as per RECIST 1.1 criteria | From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 5 years | PFS is defined as the time interval from the randomization to disease progression as per investigator assessment or death due to any cause |
| Secondary | OS | From the date of randomization to the date of death due to any cause; Up to approximately 5 years | Overall survival (OS) is defined as the time interval from randomization to death due to any cause |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06935409
GET https://conductscience.org/api/trials/v1/NCT06935409/registered